Remove 2022 Remove Biosimilars Remove Process Improvement
article thumbnail

Single-use technology propelling upstream bioprocessing market expansion

European Pharmaceutical Review

percent between 2022 and 2029. The rising productivity of cell lines has improved the performance of upstream processing with low cost and high process reproducibility, the report explained. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78

article thumbnail

The next frontier: Global leadership in biopharma

Express Pharma

Sasmitha Sahu, Managing Consultant, GlobalData states, “While India has demonstrated success in generic drug production, the same is not true for novel and biosimilar biopharma products.” As per IBER Report 2023, in 2022, 1390 new biotech startups joined the ecosystem, bringing the 10-year total to 6,755, at a CAGR of 29.8